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Abstract Changes in the levels of specific microRNAs
(miRNAs) can reduce glucose-stimulated insulin secretion
and increase beta-cell apoptosis, two causes of islet dys-
function and progression to type 2 diabetes. Studies have
shown that single nucleotide polymorphisms (SNPs) within
miRNA genes can affect their expression. We sought to
determine whether miRNAs, with a known role in beta-cell
function, possess SNPs within the pre-miRNA structure
which can affect their expression. Using published litera-
ture and dbSNP, we aimed to identify miRNAs with a role
in beta-cell function that also possess SNPs within the
region encoding its pre-miRNA. Following transfection of
plasmids, encoding the pre-miRNA and each allele of the
SNP, miRNA expression was measured. Two rare SNPs
located within the pre-miRNA structure of two miRNA
genes important to beta-cell function (miR-34a and miR-
96) were identified. Transfection of INS-1 and MIN6 cells
with plasmids encoding pre-miR-34a and the minor allele
of rs72631823 resulted in significantly (p \ 0.05) higher
miR-34a expression, compared to cells transfected with
plasmids encoding the corresponding major allele. Simi-
larly, higher levels were also observed upon transfection of
HeLa cells. Transfection of MIN6 cells with plasmids
encoding pre-miR-96 and each allele of rs41274239
resulted in no significant differences in miR-96 expression.
A rare SNP in pre-miR-34a is associated with increased
levels of mature miR-34a. Given that small changes in
miR-34a levels have been shown to cause increased levels
of beta-cell apoptosis this finding may be of interest to
studies looking at determining the effect of rare variants on
type 2 diabetes susceptibility.
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Introduction
Recent genome-wide association studies (GWAS) have
identified common (minor allele frequency (MAF) [5 %)
single nucleotide polymorphisms (SNPs) associated with risk
of type 2 diabetes [1, 2]. Most of these SNPs seem to exert their
effect by affecting beta-cell function, rather than insulin action
[3]. However, despite some success, these findings only
explain*10 % of the heritability of type 2 diabetes [1]. It has
been widely postulated that rare genetic variation (MAF
\1 %) could explain some of the ‘‘missing heritability’’ [4, 5].
MicroRNAs (miRNAs) are single-stranded, non-protein
coding RNAs *21–23 nucleotides in length that regulate
gene expression by binding to mRNAs, via complementary
base pairing, resulting in mRNA decay and/or translational
repression. Recent studies are revealing important roles for
specific miRNAs in regulating beta-cell functions, partic-
ularly glucose-stimulated insulin secretion and apoptosis
(reviewed in [6]). In rodent models, during the progression
to diabetes, expression of specific miRNAs has been shown
to change, and manipulating the levels of these miRNAs by
silencing or mimicry experiments has revealed a causal
role in beta-cell dysfunction [7].
Given the need to tightly control the levels of specific
miRNAs for correct beta-cell function, we sought to deter-
mine whether SNPs present within the precursor-miRNA
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(pre-miRNA) structure might affect their expression. Pre-
vious studies have shown that sequence variation within a
pre-miRNA can affect levels of mature miRNA [8, 9]. The
density of SNPs within a pre-miRNA has been shown to
be lower than the SNP density in the flanking regions [10],
and as a result of this constraint SNPs that are present
would seem to have arisen fairly recently, meaning that the
MAF is low, population-specific and not captured well by
GWAS [11, 12]. Any significant associations found in this
study, between SNPs with a low MAF and miRNA
expression, may be of interest to future studies looking at
the effect of rare genetic variation on risk of developing
type 2 diabetes.
Materials and methods
Plasmids (pCMV–MIR series) encoding human pre-miR-
34a and pre-miR-96, and their flanking regions (at least
284 bp on either side), were purchased from Origene
(Rockville, MD, USA). Site-directed mutagenesis was
conducted using the QuikChange II XL Site-Directed
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA,
USA). The correct sequence for each construct was con-
firmed by Sanger sequencing.
For all cell lines, transient transfections were performed
using Nucleofector technology (Lonza, Basel, Switzerland)
at a density of 1 9 106 cells/transfection. After incubating
for 16–24 h, cells were washed in PBS three times, and then
total RNA, including miRNA, extracted using the miR-
VANA miRNA isolation kit (Life Technologies, Carlsbad,
CA, USA).
For miRNA expression analysis, RNA was reverse tran-
scribed using the miRNA reverse transcription kit (Life
Technologies) and miRNA-specific RT primers. Subse-
quently, miRNA expression levels were determined using
miRNA-specific TaqMan assays on the ABI Prism 7900HT
real-time PCR platform (Life Technologies). The GeNorm
algorithm [13] in RealTime StatMiner software (Integro-
mics, Madrid, Spain) was used to identify the most stable
housekeeping genes and thus to normalise miRNA expres-
sion levels. The following sets of genes were selected as
housekeeping genes: U6, 4.5S and U87 (INS-1); U6, RNU44
and RNU6B (HeLa); U6, snoRNA412 and snoRNA234
(MIN6). For green fluorescent protein (GFP) expression
analysis, RNA was first DNase-treated using the Turbo
DNA-free kit (Life Technologies), before being reverse
transcribed using Superscript III reverse transcriptase (Life
Technologies) and random hexamer primers. All qPCR
reactions were run on the ABI Prism 7900HT real-time PCR
platform (Life Technologies). A custom TaqMan gene
expression assay to measure GFP mRNA was designed
(Life Technologies) and its ability to robustly determine
expression levels validated by standard curve. GFP mRNA
levels were normalised using the GeNorm algorithm [13] in
RealTime StatMiner software (Integromics, Madrid, Spain)
with the following sets of genes selected as housekeeping
genes: 18S, ACTB and GUSB (HeLa); Gusb, B2m and Actb
(INS-1); B2m, Hmbs and Polr2a (MIN6). Expression of
miR-96 and miR-34a was made relative to the expression of
the respective miRNA in cells transfected with the major
allele of each SNP. To normalise for differences in trans-
fection efficiency, miRNA expression was subsequently
normalised to the expression of GFP mRNA in that
respective sample. Statistical analysis was determined using
Student’s t-test with unequal variances assumed.
Results
In dbSNP version 135, we identified three SNPs within the
pre-miRNA sequence of miRNAs important to beta-cell
function (Table 1). All SNPs had to have been found in at
least one HapMap individual to be included. For a miRNA
to be included in our study, we required there to be evi-
dence in the literature for an effect of over-expression or
silencing of that miRNA on beta-cell apoptosis or glucose-
stimulated insulin secretion. Three SNPs were identified
(rs2910164, MAF = 0.38; rs72631823, MAF = 0.001;
rs41274239, MAF = 0.002), two of which are located
within the terminal loop region of the pre-miRNA and one
within the miR* seed sequence. We chose not to study the
effects of rs2910164 on miR-146a expression as this is a
common SNP, and the effect on miR-146a expression has
been previously extensively studied [14–16].
In MIN6 cells, transfection of plasmids encoding miR-
34a and the A (minor) allele of rs72631823 resulted in 2.1-
fold higher expression of miR-34a compared to cells
transfected with plasmids encoding miR-34a and the G
(major) allele of rs72631823 (p = 0.01) (Fig. 1). A
Table 1 miRNAs with a proven role in regulating glucose-stimulated
insulin secretion and/or beta-cell apoptosis
Pre-miRNA SNP? Location of SNP References
miR-375 No N/A [28]
miR-34a Yes—rs72631823 Terminal loop [20]
miR-146a Yes—rs2910164 miR* seed [7]
miR-21 No N/A [7]
miR-96 Yes—rs41274239 Terminal loop [29]
miR-410 No N/A [30]
miR-200a No N/A [30]
miR-130a No N/A [30]
miR-9 No N/A [31]
miR-124 No N/A [29]
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similarly increased level of miR-34a expression from
plasmids bearing the minor (A) allele of rs72631823 was
seen in INS-1 cells (3.8-fold, p = 0.02) and HeLa cells
(2.5-fold, p = 0.08) (Fig. 1). Using the Mfold algorithm
[17] and web server (http://mfold.rna.albany.edu/), RNA
secondary structure predictions support these findings. The
terminal loop of the pre-miRNA bearing the A allele of
rs72631823 is in a more relaxed, open form than the G
allele (Fig. 2). This has been shown to be associated
with more efficient Drosha and Dicer processing and
consequently higher levels of mature miRNA [18]. In
MIN6 cells, transfection of plasmids encoding miR-96 and
each allele of rs41274239 resulted in no significant dif-
ferences in miR-96 expression (data not shown). This was
despite a *eightfold increase in miR-96 expression being
measured in cells transfected with plasmids encoding miR-
96, and the T (major) allele of rs41274239 compared to
cells transfected with empty vector. This finding is con-
sistent with a previous study that did not identify any
significant differences in miR-96 expression upon trans-
fection of HeLa cells with miR-96 expression plasmids
encoding each allele of rs41274239 [19].
Discussion
Two studies have shown that precise control of miR-34a
expression in the beta cell is needed to maintain correct
beta-cell function. Experiments demonstrated that palmi-
tate and proinflammatory cytokine-induced beta-cell
apoptosis result in a threefold to fourfold increase in miR-
34a expression and that specifically inhibiting miR-34a
activity significantly reduces the stimulus-induced apop-
tosis [7, 20]. One may conclude from these experiments
that miR-34a plays a causal role in beta-cell apoptosis and
that small (within one order of magnitude) changes in
expression, such as those observed in this study and
attributable to allelic effects of rs72631823, may have
significant consequences.
Our finding of increased miR-34a expression in all three
cell lines transfected with the minor versus major allele of
rs72631823 suggests that this may not be a tissue-specific
phenomenon. Indeed, small deviations in miR-34a
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Fig. 1 miRNA expression in cells transfected with plasmids encod-
ing pre-miR-34a and each allele of rs72631823. For each cell line,
expression is relative to cells transfected with the pre-miRNA
encoding the major allele of rs72631823. Data are presented as
mean ± SEM and the results of three independent transfections.
Statistical analysis performed using Student’s t-test with unequal
variances assumed. *p \ 0.05
rs72631823 major (G) allele 
rs72631823 minor (A) allele 
Fig. 2 Secondary structure of pre-miR-34a for each allele of rs72631823, as predicted by Mfold
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expression may have functional consequences in other
tissues that play a role in diabetes pathogenesis. Numerous
studies have found elevated miR-34a expression in fatty
livers of dietary-induced and genetic mouse models of
obesity [21–23]. Furthermore, higher miR-34a levels are
seen in livers of human individuals with nonalcoholic fatty
liver disease [21, 24]. A causal role for miR-34a in meta-
bolic dysregulation within the liver, through regulation of
the hepatic response to FGF19, has also been reported [25].
This suggests that increased hepatic miR-34a expression,
which may be found in carriers of the rare allele of
rs72631823, could promote a more insulin-resistant state
and compound the deleterious effects on islet function of
higher miR-34a expression. Additionally, the seeming lack
of tissue specificity for the effect of rs72631823 on miR-
34a expression suggests that results from any future
expression quantitative trait loci (eQTL) analysis in an
accessible tissue may be justifiably, and with some confi-
dence, extrapolated to more disease relevant, but inacces-
sible, tissues. The very low MAF and identification
exclusively in the Yoruba in Ibadan (YRI) population make
eQTL studies for rs72631823, however, a very difficult
avenue to pursue.
Given recent studies reporting an association of common
genetic variation within pre-miRNAs with type 2 diabetes
susceptibility [26] and an enrichment of T2D GWAS signals
in genes predicted to be targeted by islet-expressed miRNAs
[27], the importance of miRNAs to maintenance of beta-cell
function cannot be overstated. Indeed, the results of this
study may justify analysing a far larger number of SNPs
within miRNA genes (perhaps limited to those expressed in
the pancreatic islet) and assessing their effects on miRNA
expression. Whilst their rarity impedes the finding of sig-
nificant associations in single-marker tests, methods such as
the one presented here can be used to functionally annotate
variants for grouping in collapsed/multiple marker tests,
which are more likely to uncover significant associations
with complex traits, such as type 2 diabetes.
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